Welcome to our dedicated page for Adagene American Depositary Shares news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene American Depositary Shares stock.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company specializing in the discovery and development of novel antibody-based cancer immunotherapies. Co-founded by two serial entrepreneurs, Adagene aims to become a leader in antibody discovery and engineering. The company has developed a proprietary Dynamic Precision Library (DPL), showcasing its capabilities through a unique pipeline of innovative antibody therapeutics advancing into clinical trials.
The company's proprietary technologies, including NEObody™, SAFEbody®, and POWERbody™, enable the design of therapeutic antibody candidates with functional epitopes and cross-reactivity across species. These innovations are particularly focused on cancer immunotherapy, where Adagene’s pipeline features monoclonal antibody drugs targeting various cancers.
Adagene has raised over $86 million through three series of financing, with significant investments from F-Prime Capital, Eight Roads Ventures China, 6 Dimensions Capital, GP Healthcare Capital, Sequoia China, and New World TMT. The company utilizes computational biology and artificial intelligence to address unmet patient needs, striving to transform the discovery and development of therapies with enhanced safety and efficacy profiles.
One of Adagene’s key advancements is the development of ADG126, a masked anti-CTLA-4 SAFEbody, which is currently in clinical trials. Recent data highlighted no dose-limiting toxicities and compelling safety when combined with anti-PD-1 therapy. The results indicated tumor shrinkage in cold tumors and partial responses in multiple tumor types. Another notable candidate, ADG116, an unmasked anti-CTLA-4 NEObody, has also shown promising safety and anti-tumor activity in clinical trials.
Adagene’s strategic collaborations with global biopharmaceutical companies, including Roche, Sanofi, and Exelixis, emphasize the commercial potential of its antibody technologies. These partnerships leverage Adagene's platform for developing advanced therapies, including antibody-drug conjugates and bispecific antibodies, addressing a wide range of cancer types.
Financially, Adagene reported a cash balance of $143.8 million at the end of 2022, supporting streamlined operations into 2025. The company continues to prioritize its clinical programs and collaborations, aiming to maximize the therapeutic potential of its proprietary technologies.
For more information, please visit Adagene’s investor website.
Adagene Inc. (Nasdaq: ADAG) has reported promising interim results from its ongoing phase 1b/2 trials for ADG126, a masked anti-CTLA-4 SAFEbody. The trials, which presented findings at the AACR Annual Meeting, highlight a combination therapy with anti-PD-1 treatments showing tumor shrinkage and stable disease in previously untreated patients. Specifically, 22.6% of patients experienced Grade 3 treatment-related adverse events (TRAEs), indicating a best-in-class safety profile. Notably, clinical responses were observed with three partial responses and significant tumor shrinkage in patients with metastatic colorectal cancer. Additionally, ongoing dose expansion studies aim to further evaluate disease control rates and overall survival. Partnerships with Roche are also set to explore ADG126 in combination with other therapies for advanced HCC.
Adagene Inc. (Nasdaq: ADAG) reported its financial results for 2022, highlighting a cash balance of US$143.8 million to support operations through 2025. The company presented favorable clinical data for its anti-CTLA-4 programs, including ADG116 and ADG126, demonstrating best-in-class safety and efficacy profiles. Collaborations with Roche and Sanofi offer a potential multi-billion dollar non-dilutive funding opportunity. However, Adagene experienced a net loss of US$80.0 million, reflecting increased R&D expenses to advance its pipeline. Positive trial results and strategic collaborations aim to enhance shareholder value.
Adagene Inc. (Nasdaq: ADAG) announced significant developments in its clinical trials during the AACR Annual Meeting 2023. Key highlights include the presentation of ADG126 phase 1b/2 trial results, showcasing its effectiveness in combination with anti-PD-1 therapies. Findings indicate compelling safety and confirmed clinical responses, with particular attention to late-onset toxicity when combined with pembrolizumab. Additionally, details on ADG153, a new masked anti-CD47 IgG1 SAFEbody, reveal strong anti-tumor activity in preclinical models. Presentations are scheduled from April 14-19, 2023, in Orlando, Florida.
Adagene Inc. (Nasdaq: ADAG) announces the appointment of Professor Aurélien Marabelle to its Scientific and Strategic Advisory Board. Professor Marabelle, an expert in oncology and immunology, has significant experience in early-phase clinical trials of cancer immunotherapies. His research focuses on targeting tumor-specific regulatory T-cells (Tregs) using Adagene’s SAFEbody technology for effective systemic delivery of anti-CTLA-4 therapies. This strategic addition is expected to enhance Adagene’s understanding of tumor-specific Treg depletion, further strengthening its pipeline of innovative immunotherapy programs.
Adagene Inc. (Nasdaq: ADAG) announced positive data for its anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy for advanced solid tumors. In a study of 14 patients, no dose-limiting toxicities were observed with ADG126, demonstrating a compelling safety profile. The trial also showed confirmed partial responses and ongoing tumor shrinkage in multiple tumor types, including resistant variants. The company is expanding dose optimization strategies in line with the FDA's Project Optimus initiative, looking to enhance therapeutic efficacy while minimizing toxicity.
Adagene Inc. (Nasdaq: ADAG) announces that CEO Peter Luo will present a corporate update at the Biotech Showcase™ 2023 on January 9-11 in San Francisco, coinciding with the J.P. Morgan Healthcare Conference. The presentation is scheduled for 11:30 a.m. Pacific time at the Hilton San Francisco, Union Square. A live webcast will be available on Adagene's investor website, with a replay accessible for 30 days. Adagene focuses on developing novel antibody-based cancer immunotherapies using advanced technologies like its Dynamic Precision Library.
Adagene Inc. (Nasdaq: ADAG) announced a collaboration with Roche to evaluate its ADG126 in combination with Roche's atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma (HCC). The trial will be a randomized phase 1b/2 study, initially involving 60 patients. Adagene retains global rights for ADG126. This collaboration seeks to improve treatment efficacy in a disease with a high mortality rate, leveraging Adagene's SAFEbody technology to enhance safety and efficacy while addressing the challenges of combining therapies.
Adagene Inc. (Nasdaq: ADAG) announced interim phase 1b/2 clinical data for its anti-CTLA-4 antibody ADG116, showcased at the Society for Immunotherapy of Cancer Annual Meeting. Significant findings include: two partial responses in Kaposi’s sarcoma and renal cell carcinoma as monotherapy, and a confirmed durable complete response in head and neck cancer when combined with toripalimab. Additionally, ADG116 demonstrated a potent activity in microsatellite-stable colorectal cancer, with no dose-limiting toxicities reported. The overall disease control rate reached 33% across monotherapy dose levels.
Adagene Inc. (Nasdaq: ADAG) has announced the presentation of clinical data for its anti-CTLA-4 antibody candidate, ADG116, at the SITC Annual Meeting on November 10, 2022. The phase 1b/2 studies demonstrate a differentiated safety profile across dosing levels, including monotherapy and combination with anti-PD-1 therapies. Notably, the data highlights anti-tumor activity in both warm and cold tumors, as well as objective responses in tumor types lacking approved anti-CTLA-4 treatments. The findings will be available on Adagene's website post-presentation.
FAQ
What is the current stock price of Adagene American Depositary Shares (ADAG)?
What is the market cap of Adagene American Depositary Shares (ADAG)?
What is Adagene's main focus?
What technologies has Adagene developed?
Who are Adagene's significant investors?
What is the status of Adagene's clinical candidate ADG126?
What are some of Adagene's strategic collaborations?
What financial position did Adagene report at the end of 2022?
Where can I find more information about Adagene?
What is the significance of Adagene's technology collaborations?
Who co-founded Adagene?
What are the main therapeutic areas targeted by Adagene's pipeline?
